Similar Articles
1361 Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications
1362 Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis
1363 A polymorphism within ErbB4 is associated with risk for hepatocellular carcinoma in Chinese population
1364 Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells
1365 Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated?
1366 Hepatitis B virus infection and the risk of hepatocellular carcinoma
1367 Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma
1368 Liver transplantation for hepatocellular carcinoma on cirrhosis: Strategies to avoid tumor recurrence
1369 Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization
1370 CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA